Our Mission

Established in 2013, the Oklahoma Clinical and Translational Science Institute serves as a catalyst for clinical and translational research that improves health and healthcare for underserved and underrepresented populations, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Shared Clinical and Translational Resources

OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

BERD Short Course on Biases in Diagnostic and Prognostic Research

Submitted by tvanwagoner on

https://osctr.ouhsc.edu/short-course

This seminar/workshop will provide a brief overview of study designs for and common biases affecting diagnostic test accuracy and prognostic studies.  Numerical examples  will be used to illustrate the impact of common biases.

3/31/2023 Noon - 1:30 pm (CDT)

Hudson College of Public Health Auditorium (CHB 150)

Lunch Provided for first 25 in-person participants

Registration Link

Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards

Submitted by tvanwagoner on

This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.

Plasma Exosomes Show Promise for Early Detection of Pancreatic Cancer

Submitted by Anonymous (not verified) on

Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and pancreatic cancer has some of the lowest 5-year survival rates of any cancer. Early detection can improve survival rates. When pancreatic ductal adenocarcinoma is initially diagnosed at stage IV, patients have a 2.7% 5-year survival rate. When diagnosis occurs at Stage I or IIA, this improves to 34%. However, there are currently no accurate blood tests for early detection of pancreatic cancer.

Subscribe to News

Recent Publications

Oxidized high-density lipoprotein and low-density lipoprotein in adolescents with obesity and metabolic dysfunction-associated steatotic liver disease

Pediatr Obes. 2024 Dec 16:e13194. doi: 10.1111/ijpo.13194. Online ahead of print.

ABSTRACT

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly common in the pediatric population and may increase risk for developing cardiovascular disease (CVD) in people with MASLD. Oxidized high-density lipoprotein (oxHDL) and oxidized low-density lipoprotein (oxLDL) are modified, pro-atherosclerotic lipoproteins that are increased in adults with MASLD and CVD but have not been reported in adolescents with MASLD.

Media

Upcoming Events

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies